Atacicept in Multiple Glomerular Diseases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age2+
SponsorVera Therapeutics, Inc.
About this trial
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Eligibility criteria
Qualifiers
Weight of at least 40 kg
On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease
Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.
Age ≥ 18 years
Disqualifiers
Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)
Active viral or bacterial infections
Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study
Administration of live and live-attenuated vaccinations within 30 days prior to enrollment
Trial design
Treatments tested in this trial
- Atacicept
Treatment groups
250 Participants
are divided into 3 treatment groupsLocations
1Vera Therapeutics94005, BrisbaneCalifornia, United States
Sponsors and collaborators
Vera Therapeutics, Inc.
Lead sponsor
Source ClinicalTrials.gov